Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is New Ray Medicine International Holding Gross Margin %?
New Ray Medicine International HoldingHKSE:06108 52 Gross Margin % is 14.61% as of Dec. 2025, which is 16% above its 10-year median of 12.64. GuruFocus rates HKSE:06108 with a GF Score™ of 52/100 and a GF Value™ of HK$1.04 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 634 Healthcare Providers & Services companies, New Ray Medicine International Holding ranks worse than 93.38% on this metric.
HKSE:06108's Gross Margin % is ranked worse than 93.38% of 634
companies
in the Healthcare Providers & Services industry
Industry Median: 40.245
vs HKSE:06108: 12.39
New Ray Medicine International Holding had a gross margin of 14.61% for the quarter that ended in Dec. 2025 => No sustainable competitive advantage
New Ray Medicine International Holding (HKSE:06108) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
New Ray Medicine International Holding had a gross margin of 14.61% for the quarter that ended in Dec. 2025 => No sustainable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
New Ray Medicine International Holding Gross Margin % Related Terms
New Ray Medicine International Holding Gross Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
New Ray Medicine International Holding Gross Margin % Chart
New Ray Medicine International Holding Annual Data
New Ray Medicine International Holding Gross Margin % Competitor Comparison
For the Pharmaceutical Retailers subindustry, New Ray Medicine International Holding's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
New Ray Medicine International Holding Gross Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, New Ray Medicine International Holding's Gross Margin % distribution charts can be found below:
* The bar in red indicates where New Ray Medicine International Holding's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
New Ray Medicine International Holding (HKSE:06108) has a Gross Margin % of 14.61% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on New Ray Medicine International Holding and its competitors. This is 16% above median its historical median of 12.64. Over the past decade, New Ray Medicine International Holding's Gross Margin % has ranged from 8.21 to 25.80. According to the industry distribution chart, New Ray Medicine International Holding ranks #592 out of 634 companies in the Healthcare Providers & Services industry, placing it in the top 93.4%.
Is New Ray Medicine International Holding's Gross Margin % too high?
New Ray Medicine International Holding's current Gross Margin % of 14.61% is 16% above median its 10-year median of 12.64. Over the past 10 years, this metric has ranged from a low of 8.21 to a high of 25.80. The Healthcare Providers & Services industry median Gross Margin % is 40.25. New Ray Medicine International Holding's value of 14.61% is 63.7% below this industry median. Based on the distribution chart, New Ray Medicine International Holding ranks #592 out of 634 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, New Ray Medicine International Holding has a GF Score™ of 52/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does New Ray Medicine International Holding's Gross Margin % compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, New Ray Medicine International Holding ranks #592 out of 634 companies for Gross Margin %. This places New Ray Medicine International Holding in the lower half of its industry. The industry median Gross Margin % is 40.25. New Ray Medicine International Holding's value of 14.61% is 63.7% below this benchmark. Historically, New Ray Medicine International Holding's own Gross Margin % has ranged from 8.21 to 25.80 over the past decade. While the company's 10-year median is 12.64 vs. the industry median of 40.25, New Ray Medicine International Holding has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Healthcare Providers & Services company?
The median Gross Margin % among Healthcare Providers & Services companies is 40.25, based on 634 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. New Ray Medicine International Holding's current Gross Margin % of 14.61% is 63.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on New Ray Medicine International Holding and its competitors. For the Healthcare Providers & Services industry, the median Gross Margin % is 40.25 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. New Ray Medicine International Holding's current Gross Margin % is 14.61%, which is 16% above median its own 10-year median of 12.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is New Ray Medicine International Holding stock overvalued right now?
Based on GuruFocus' analysis, New Ray Medicine International Holding (HKSE:06108) is currently considered Possible Value Trap. The stock's GF Value™ is HK$1.04, compared to a current price of HK$0.23 — trading 78.4% below its estimated fair value. The current Gross Margin % is 14.61%, which is 16% above median its 10-year median of 12.64 and 63.7% below the Healthcare Providers & Services industry median of 40.25. New Ray Medicine International Holding's overall GF Score™ is 52/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For New Ray Medicine International Holding (HKSE:06108), the current Gross Margin % is 14.61% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is New Ray Medicine International Holding (HKSE:06108) Overvalued in 2026?
Based on GuruFocus' analysis, New Ray Medicine International Holding stock appears to be undervalued.
The current stock price of HK$0.23 is trading 78.4% below its estimated GF Value™ of HK$1.04.
GuruFocus considers New Ray Medicine International Holding to be Possible Value Trap.
Key valuation signals for HKSE:06108:
Gross Margin %: 14.61% (16% above median its 10-year median of 12.64)
GF Value™: HK$1.04 vs. price of HK$0.23 (78.4% below fair value)
Industry Position: 63.7% below the Healthcare Providers & Services median (#592 of 634)
No single metric tells the full story. See the HKSE:06108 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
New Ray Medicine International Holding Ltd is engaged in the trading and distribution of pharmaceutical products in the People's Republic of China. The company's segments include the Distribution and trading of pharmaceutical products and the Provision of marketing and promotion services. Distribution and trading of pharmaceutical products segment consist of Injection drugs and generate maximum revenue for the company.
52GF Score
Get the complete analysis for HKSE:06108
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:06108 has been successfully added to your 
